Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Liqing Wu

Showing results (91-100 of 91) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 91 results.
Blood Cancer Journal|December 18, 2024
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 studyYi Zhang, Hu Zhou, Shanshan Suo, et al.
Pageof 10

Showing results (91-100 of 91) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 91 results.
Blood Cancer Journal|December 18, 2024
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 studyYi Zhang, Hu Zhou, Shanshan Suo, et al.
Pageof 10